Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Chronos Therapeutics presents orexin receptor antagonists

March 22, 2019

RGFP-966, an HDAC3 inhibitor, suppresses drug-seeking behavior in rats

Feb. 21, 2019

GPR39 agonist reduces alcohol intake in mouse model of alcohol use disorder

Feb. 19, 2019

Addex and Indivior intend to accelerate additional GABA-B PAM compounds for addiction

Feb. 14, 2019

Antidote Therapeutics to collaborate with NCI on development of ATI-1013

Feb. 8, 2019

Phase Ib data support expansion of indication for BioXcel's BXCL-501

Feb. 5, 2019

Phase II data for PF-04457845 as potential treatment of cannabis withdrawal and dependence

Jan. 15, 2019

Nanoscavenger versus neurotoxins

Jan. 7, 2019

ITI-333 shows promise for the treatment of pain and substance abuse-derived disorders

Dec. 24, 2018

Adial engages CRO to oversee phase III trial of AD-04 for alcohol use disorder

Nov. 23, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....